Levodopa

CHEMBL1009 Phase 4 معتمد Small molecule

Half-Life

1.5 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

197.2 g/mol

LogP

-2.7

Phase

4

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

الوزن الجزيئي

197,1880 g/mol

LogP

-2,70

TPSA

104,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Age-Related Macular Degeneration Pain Management Asthma Alzheimer's Disease Parkinson's Disease Schizophrenia Generalized Anxiety Disorder Stroke Type 2 Diabetes Major Depressive Disorder Chronic Pain

تصنيفات الأدوية

N — N - Nervous System

آلية العمل

Metabolic precursor of dopamine that crosses the BBB.

Pharmacokinetics (PK)

Half-Life 1.5 hours

Pharmacodynamics (PD)

الآلية

Metabolic precursor of dopamine that crosses the BBB.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O

InChI

InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

Molecular Formula

C9H11NO4

HBD / HBA

4 / 5

الروابط القابلة للدوران

3

الذرات الثقيلة

14

DRD2 (Dopamine D2 Receptor) Agonist

Primary Target

ABCB1 (P-glycoprotein) Substrate

Major Levodopa + Quetiapine

Quetiapine, a D2 receptor antagonist, pharmacodynamically opposes levodopa's dopaminergic effect, worsening Parkinson's disease motor symptoms.

Major Levodopa + Aripiprazole

Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.

Moderate Levodopa + Carbamazepine

Carbamazepine may reduce levodopa efficacy through enzyme induction and pharmacodynamic antagonism, potentially worsening Parkinson's disease control.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

Metabolic precursor of dopamine that crosses the BBB.

Key pharmacokinetic parameters for Levodopa: Half-life: 1.5 hours.

Yes, Levodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Acetaminophen Small molecule Aspirin Small molecule Sertraline Small molecule Escitalopram Small molecule

Same Target

Quetiapine Small molecule Aripiprazole Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1009. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6047. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Levodopa على PillFYI

البنية

بيانات سريعة

Class: N - Nervous System
الصيغة الجزيئية: C9H11NO4
المرادفات: 11

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Levodopa

المجالات العلاجية

تصنيفات الأدوية

آلية العمل

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

Cite this structure

Embed this structure

No side effects recorded

الأسئلة الشائعة

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget